Esteban-Casado S, de Rosales Cabrera AMM, Pérez AU, et al. - This observational cross-sectional study was undertaken to determine if a combined treatment sclerotherapy and topical therapy with propranolol 0.5% nasal formulation would decrease the epistaxis due to hereditary hemorrhagic telangiectasia (HHT) and improve quality of life of patients. In total, 38 consecutive patients (mean age: 57.2 years) subjected to the combined treatment were assessed. Investigators found that combined therapy (sclerotherapy and topical nasal propranolol) significantly reduced epistaxis as a result of HHT and increased the quality of life for patients.